A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in preventing or delaying of bone metastasis in patients with stage III non-small cell lung cancer

Trial Profile

A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in preventing or delaying of bone metastasis in patients with stage III non-small cell lung cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2015

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone metastases; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 22 Jun 2012 Results published in Annals of Oncology.
    • 20 Jul 2011 Actual patient number is 437 as reported by as reported by ClinicalTrials.gov.
    • 19 May 2011 Additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top